Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and KIF5B-MET fusion

Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and KIF5B-MET fusion

BackgroundThe c-met proto-oncogene (MET) serves as a significant primary oncogenic driver in non-small cell lung cancer (NSCLC) and has the potential to fuse with other genes, such as KIF5B, although it occurs infrequently. Only a limited number of reported cases have examined the clinical efficacy...

Full description

Bibliographic Details
Main Authors: Su-Su Dong, Wen Dong, Ya-Fen Tan, Qiang Xiao, Tian-Li Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Oncology
Subjects:
acquired resistance
MET fusion
non-small cell lung cancer
gene mutations
crizotinib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1370901/full

Similar Items

Similar Items